426 related articles for article (PubMed ID: 17925313)
21. Microbiologic surrogate end points in clinical trials of infectious diseases: example of acute otitis media trials.
Powers JH
Pharmacotherapy; 2005 Dec; 25(12 Pt 2):109S-123S. PubMed ID: 16305280
[TBL] [Abstract][Full Text] [Related]
22. Biomarkers in Alzheimer's disease: not yet surrogate endpoints.
Coley N; Andrieu S; Delrieu J; Voisin T; Vellas B
Ann N Y Acad Sci; 2009 Oct; 1180():119-24. PubMed ID: 19906266
[TBL] [Abstract][Full Text] [Related]
23. What does it need to be a biomarker? Relationships between resolution, differential quantification and statistical validation of protein surrogate biomarkers.
Schrattenholz A; Groebe K
Electrophoresis; 2007 Jun; 28(12):1970-9. PubMed ID: 17516580
[TBL] [Abstract][Full Text] [Related]
24. The uses of biomarkers in drug development.
Hurko O
Ann N Y Acad Sci; 2009 Oct; 1180():1-10. PubMed ID: 19906255
[TBL] [Abstract][Full Text] [Related]
25. LDL-cholesterol differences predicted survival benefit in statin trials by the surrogate threshold effect (STE).
Johnson KR; Freemantle N; Anthony DM; Lassere MN
J Clin Epidemiol; 2009 Mar; 62(3):328-36. PubMed ID: 18834708
[TBL] [Abstract][Full Text] [Related]
26. The use of surrogate endpoints in clinical trials: focus on clinical trials in cardiovascular diseases.
Lonn E
Pharmacoepidemiol Drug Saf; 2001; 10(6):497-508. PubMed ID: 11828831
[TBL] [Abstract][Full Text] [Related]
27. Biomarkers and surrogate end points for fit-for-purpose development and regulatory evaluation of new drugs.
Wagner JA; Williams SA; Webster CJ
Clin Pharmacol Ther; 2007 Jan; 81(1):104-7. PubMed ID: 17186007
[TBL] [Abstract][Full Text] [Related]
28. A unified framework for the evaluation of surrogate endpoints in mental-health clinical trials.
Molenberghs G; Burzykowski T; Alonso A; Assam P; Tilahun A; Buyse M
Stat Methods Med Res; 2010 Jun; 19(3):205-36. PubMed ID: 19608602
[TBL] [Abstract][Full Text] [Related]
29. [Clinical evaluation: from intermediate to surrogate criteria].
Boissel JP; Perret L; Bouvenot G; Castaigne A; Gérard-Coué MJ; Maillère P; Mismetti P; Vray M
Therapie; 1997; 52(4):281-5. PubMed ID: 9437878
[TBL] [Abstract][Full Text] [Related]
30. [Controlled randomized clinical trials].
Jaillon P
Bull Acad Natl Med; 2007; 191(4-5):739-56; discussion 756-8. PubMed ID: 18225427
[TBL] [Abstract][Full Text] [Related]
31. Meta-analyses evaluating surrogate endpoints for overall survival in cancer randomized trials: A critical review.
Savina M; Gourgou S; Italiano A; Dinart D; Rondeau V; Penel N; Mathoulin-Pelissier S; Bellera C
Crit Rev Oncol Hematol; 2018 Mar; 123():21-41. PubMed ID: 29482777
[TBL] [Abstract][Full Text] [Related]
32. A comment on: statistical evaluation of biomarkers as surrogate endpoints: a literature review by C. J. Weir and R. J. Walley, Statistics in Medicine 2006; 25:183-203.
Ditlevsen S; Keiding N
Stat Med; 2007 Mar; 26(6):1415-6. PubMed ID: 16847904
[No Abstract] [Full Text] [Related]
33. Surrogate marker evaluation from an information theory perspective.
Alonso A; Molenberghs G
Biometrics; 2007 Mar; 63(1):180-6. PubMed ID: 17447943
[TBL] [Abstract][Full Text] [Related]
34. Individual- and trial-level surrogacy in colorectal cancer.
Buyse M; Burzykowski T; Michiels S; Carroll K
Stat Methods Med Res; 2008 Oct; 17(5):467-75. PubMed ID: 18285439
[TBL] [Abstract][Full Text] [Related]
35. Change in MRI striatal volumes as a biomarker in preclinical Huntington's disease.
Aylward EH
Brain Res Bull; 2007 Apr; 72(2-3):152-8. PubMed ID: 17352939
[TBL] [Abstract][Full Text] [Related]
36. Advanced topics in evidence-based urologic oncology: surrogate endpoints.
Lavallée LT; Montori VM; Canfield SE; Breau RH
Urol Oncol; 2011; 29(4):447-53. PubMed ID: 21726795
[TBL] [Abstract][Full Text] [Related]
37. Semiparametric inference for surrogate endpoints with bivariate censored data.
Ghosh D
Biometrics; 2008 Mar; 64(1):149-56. PubMed ID: 17651457
[TBL] [Abstract][Full Text] [Related]
38. Evaluating correlation-based metric for surrogate marker qualification within a causal correlation framework.
Wang Y; Mogg R; Lunceford J
Biometrics; 2012 Jun; 68(2):617-27. PubMed ID: 22059475
[TBL] [Abstract][Full Text] [Related]
39. Does the decision in a validation process of a surrogate endpoint change with level of significance of treatment effect? A proposal on validation of surrogate endpoints.
Sertdemir Y; Burgut R
Contemp Clin Trials; 2009 Jan; 30(1):8-12. PubMed ID: 18809512
[TBL] [Abstract][Full Text] [Related]
40. Evidence-based medicine, systematic reviews, and guidelines in interventional pain management, part I: introduction and general considerations.
Manchikanti L
Pain Physician; 2008; 11(2):161-86. PubMed ID: 18354710
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
